Judicial Coherence in the European Patent System, Lessons from the US and Japan, by Federica Baldan, Postdoctoral Researcher, Faculty of Law, University of Antwerp, Belgium and FWO Postdoctoral Researcher, fellowship number 1257321N, Research Foundation Flanders, Belgium The blurb: “This comprehensive book examines the judicial governance of the patent system in Europe and beyond, and looks […]
FOUND IN: BLOGHE Licenties B.V. v. Orchid Gardens et al, District Court The Hague, The Netherlands, 27 July 2022, Case no. ECLI:NL:RBDHA:2022:7627 HE Licences is involved in the management of patent rights in the ornamental plants industry. Orchid Gardens cultivates plants, including colored orchids. HE Licences invoked its patent rights against customers of Orchid Gardens. HE Licences […]
FOUND IN: BLOGAmending the description prior to grant of a European patent – recent developments; reported by Dr. Klaus Reindl and Dr. Georg Anetsberger, BARDEHLE PAGENBERG For many years already, it has been common practice at the EPO to adapt the description prior to grant of a European patent to ensure that the subject-matter of the allowable […]
FOUND IN: BLOGSandoz Limited v Bristol-Myers Squibb Holdings Ireland Unlimited Company and Pfizer Inc. heard together with Teva Pharmaceutical Industries Limited v Bristol-Myers Squibb Holdings Ireland Unlimited Company and Pfizer Inc. v Teva UK Limited (Part 20 Defendant), High Court, London, UK, 15 July 2022, [2022] EWHC 1831 (Pat) Bristol-Myers Squibb and Pfizer’s formulation patents protecting formulations […]
FOUND IN: BLOGOn 13 June 2022, Lord Justice Birss provided the leading Court of Appeal judgment (to which Arnold LJ and Phillips LJ agreed) in Optis v Apple. The Court of Appeal judgment concerned Apple’s appeal in relation to whether a piece of prior art, referred to as InterDigital, anticipated claims 1, 6, and 9 of Optis’ […]
FOUND IN: BLOGNeurim and Flynn v Mylan [2022] EWCA Civ 699 Introduction The Court of Appeal dismissed Mylan’s appeal against the finding of the Patents Court that European Patent (UK) No. 3 103 443 (“EP443”), a second medical use patent for a prolonged release formulation of melatonin owned by Neurim (and under which Flynn holds an exclusive […]
FOUND IN: BLOGIn an interim relief decision of 21 June 2022, the preliminary injunction (PI) Judge of the District Court of The Hague held Novartis’ EP 2 959 894 (“EP 894”) re fingolimod 0,5 mg provisionally invalid. This is the first substantive PI decision on the validity of EP 894 matter in Europe, where several proceedings between […]
FOUND IN: BLOG
EMAIL US
